We use some essential cookies to make this website work.
We바카라 사이트™d like to set additional cookies to understand how you use 바카라 사이트, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
A study found that around 4 months after vaccination, people who received the RSV vaccine had a 79% reduction in their risk of getting lower respiratory tract disease caused by RSV, compared with those who received placebo.
This national approval was granted after an Access Consortium new active substance work-sharing initiative (NASWSI) procedure.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 14 February 2025, approved efanesoctocog alfa (brand name Altuvoct) to be used to treat and prevent bleeding in patients aged 2 years and above with s바카라 사이트¦
Gozetotide binds to the cancer cells with prostate-specific membrane antigen (PSMA) on their surface, making them visible during the PET scan.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name IXCHIQ) to protect adults against chikungunya disease, caused by the chik바카라 사이트¦
New guidance helps manufacturers navigate medical device regulations and protect users of digital mental health technologies.
It is the only example globally of an end-to-end access pathway, where a medicine developer can work collaboratively with the national health system, the regulator, and health technology assessment bodies from the early stag바카라 사이트¦
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 24 January 2025, approved garadacimab (brand name Andembry) for patients aged 12 years and older with hereditary angioedema (HAE) to prevent angioedem바카라 사이트¦
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine aprocitentan (Jeraygo) to treat hypertension (high blood pressure) in adults whose blood pressure cannot be adequately controlled by at바카라 사이트¦
As with any medicine, the MHRA will keep the safety and effectiveness of seladelpar under close review.바카라 사이트¯
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved (27 December 2024) the medicine sotatercept (Winrevair) to treat pulmonary arterial hypertension (PAH).Â
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 31 December 2024, approved the medicine tarlatamab (Imdylltra) to treat adult patients with small cell lung cancer (SCLC) that has spread throughout t바카라 사이트¦
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (20 December 2024) granted a conditional marketing authorisation for the medicine givinostat (Duvyzat) to treat Duchenne muscular dystrophy (DMD).
The Medicines and Healthcare products Regulatory Agency has approved the medicine delgocitinib (Anzupgo) to treat moderate to severe chronic hand eczema in adults when topical corticosteroids are inadequate or inappropriate.
With industry already showing a very high level of readiness, the MHRA is reminding remaining marketing authorisation holders to ensure they are prepared for the new packaging and labelling measures
The Medicines and Healthcare products Regulatory Agency has approved the medicine flortaucipir (Tauvid), given to adults with memory problems so that doctors can perform a type of brain scan called a PET.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sparsentan (Filspari) to treat primary immunoglobulin A nephropathy (IgAN).
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 30 October, approved the medicine sugemalimab (Eqjubi) to treat adult patients with a type of lung cancer called 바카라 사이트˜non-small cell lung cancer바카라 사이트™.Â
The UK will be the first country in the world to introduce a tailored framework for the regulation of innovative products manufactured at or close to the location where a patient receives care.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved elafibranor (Iqirvo) to treat adult patients with a rare type of liver disease known as primary biliary cholangitis (PBC).
Don바카라 사이트™t include personal or financial information like your National Insurance number or credit card details.
To help us improve 바카라 사이트, we바카라 사이트™d like to know more about your visit today. .